Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-707 vs Pembrolizumab in PD-L1+ Advanced NSCLC
NCT06980272Phase 3Recruiting
- Sponsor
- 3SBio
- Start
- Jun 2025
- Primary completion
- Jul 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tivunatamig in non-small cell lung cancer (NSCLC), sponsored by 3SBio. Started Jun 2025; status: recruiting.
02
Drugs
tivunatamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06980272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980272.